Stockholm-based BioTech scale-up specialising in matrix biology and cell culture,
BioLamina has raised €20M across 1 funding round from 1 investor, most recently a round in Apr 2026. Based in Stockholm, Sweden; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-04-17 | Other | €20M |
| European Investment Bank (EIB) |
| View deal → |
